Skip to main content
Article thumbnail
Location of Repository

Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction

By William H Frishman, Linda S Henderson and Mary Ann Lukas


Cardiovascular disease is the leading cause of death worldwide. Within the treatment armamentarium, beta-blockers have demonstrated efficacy across the spectrum of cardiovascular disease – from modification of a risk factor (ie, hypertension) to treatment after an acute event (ie, myocardial infarction). Recently, the use of beta-blockers as a first-line therapy in hypertension has been called into question. Moreover, beta-blockers as a class are saddled with a misperception of having poor tolerability. However, vasodilatory beta-blockers such as carvedilol have a different hemodynamic action that provides the benefits of beta-blockade with the addition of vasodilation resulting from alpha 1-adrenergic receptor blockade. Vasodilation reduces total peripheral resistance, which may produce an overall positive effect on tolerability. Recently, a new, controlled-release carvedilol formulation has been developed that provides the clinical efficacy of carvedilol but is indicated for once-daily dosing. This review presents an overview of the clinical and pharmacologic carvedilol controlled-release data

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2006). A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the “patient journey”) in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET).
  2. (2005). A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy.
  3. (2007). A historical perspective on the development of betaadrenergic blockers.
  4. (1984). A study of effi cacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension. Betaloc Compliance Canadian Cooperative Study Group. Clin Invest Med,
  5. (2001). A systematic review of the associations between dose regimens and medication compliance. Clin Ther,
  6. (2007). A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling.
  7. (2006). After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. Clin Res Cardiol,
  8. (2003). Alpha- and beta-adrenergic blocking drugs.
  9. (2005). Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial.
  10. (2007). Antioxidant activity of carvedilol in cardiovascular disease.
  11. (2002). Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? UK prospective diabetes study 61. Diabetes Care,
  12. (1997). Australia/New Zealand Heart Failure Research Collaborative Group.
  13. (2006). Beta blockers in the management of chronic kidney disease. Kidney Int,
  14. (1998). Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis,
  15. (2008). Beta-Arrestin-Mediated Signaling in the Heart. Circ J,
  16. (2007). beta-Blocker use and diabetes symptom score: results from the GEMINI study. Diabetes Obes Metab,
  17. (2004). beta-Blockers in hypertension: is carvedilol different?
  18. (2005). Cardioprotection: the role of beta-blocker therapy.
  19. (2007). Cardiovascular diseases. Fact sheet no. 317 [online]. Accessed
  20. (2007). Cardiovascular protection using beta-blockers: a critical review of the evidence.
  21. (2006). Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profi le.
  22. (2002). Carvedilol decreases elevated oxidative stress in human failing myocardium.
  23. (2004). Carvedilol differentially regulates cytokine production from activated human peripheral blood mononuclear cells. Cardiovasc Drugs Ther,
  24. (2006). COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure.
  25. (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
  26. (2007). Compliance with Once Daily Controlled Release vs Twice Daily Immediate Release Carvedilol in Patients with Heart Failure: The CASPER Trial J Card Fail,
  27. (2006). Controlled-release carvedilol in the treatment of essential hypertension.
  28. (2008). Controlled-release carvedilol.
  29. (1996). Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study.
  30. (2000). Differential effects of betablockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol.
  31. (2008). Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure.
  32. (2001). Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
  33. (2002). Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
  34. (2002). Effect of selective and nonselective betablockers on resting energy production rate and total body substrate utilization in chronic heart failure.
  35. (2007). Effects of carvedilol early after myocardial infarction: analysis of the fi rst 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN).
  36. (2004). Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation,
  37. (2007). Effects of carvedilol on plasma levels of pro-infl ammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy. Tex Heart Inst J,
  38. (2005). Effects of metoprolol and carvedilol on cause-specifi c mortality and morbidity in patients with chronic heart failure – COMET.
  39. (2007). Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).
  40. (2006). Effi cacy of a once-daily formulation of carvedilol for the treatment of hypertension.
  41. (2007). Ethanol does not alter the pharmacokinetic profi le of the controlled-release formulation of carvedilol.
  42. (1998). Fixed-dose combination therapy: panacea or poison? Intensive Care Med,
  43. (2007). Fixed-dose combinations improve medication compliance: a meta-analysis.
  44. (2003). Haemoglobin A1c – a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med,
  45. (2008). Heart disease and stroke statistics –
  46. (2007). Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev,
  47. (2003). Initial treatment of hypertension.
  48. (1998). Ischemic heart disease: the role of mitochondria – carvedilol prevents lipid peroxidation of mitochondrial membranes. Rev Port Cardiol, 17(Suppl 2):II63–77.
  49. (2007). Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial.
  50. (2004). Managing the patient with diabetes mellitus and heart failure: issues and considerations.
  51. (1997). Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.
  52. (2004). Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
  53. (2001). Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure.
  54. (2005). Myocardial substrate metabolism in the normal and failing heart. Physiol Rev,
  55. (2006). Nebivovol and carvedilol induce NO-dependent coronary vasodilatation that is unlikely to be mediated by extracellular ATP in the isolated guinea pig heart. Pharmacol Rep,
  56. (2005). Negotiating compliance in heart failure: remaining issues and questions.
  57. (2006). New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell,
  58. (2006). Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
  59. (2006). Pharmacokinetic profi le of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
  60. (2006). Pharmacokinetic properties of a new controlled-release formulation of carvedilol.
  61. (2007). Population pharmacokinetics of S(−)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. Aaps J,
  62. (1986). Prevalence and prognostic signifi cance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial.
  63. (2004). Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease.
  64. (2006). Profi le of carvedilol controlled-release: a new once-daily formulation of carvedilol.
  65. (1996). Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension.
  66. (2006). Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure.
  67. (2002). Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol.
  68. (2005). Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization.
  69. (2005). Should beta blockers remain fi rst choice in the treatment of primary hypertension? A metaanalysis.
  70. (2002). Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
  71. (2007). The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients.
  72. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.
  73. (1989). The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors. Chirality,
  74. (2007). The vasodilatory beta-blockers. Curr Hypertens Rep,
  75. (2007). Use of statins and beta-blockers after acute myocardial infarction according to income and education.
  76. (2003). Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther,
  77. (1987). Vasodilatory effects of carvedilol and pindolol.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.